397 related articles for article (PubMed ID: 19070995)
1. A pilot study of the safety and efficacy of amisulpride and risperidone in elderly psychotic patients.
Riedel M; Eich FX; Möller HJ
Eur Psychiatry; 2009 Apr; 24(3):149-53. PubMed ID: 19070995
[TBL] [Abstract][Full Text] [Related]
2. Amisulpride versus risperidone in the treatment of schizophrenic patients: a double-blind pilot study in Taiwan.
Hwang TJ; Lee SM; Sun HJ; Lin HN; Tsai SJ; Lee YC; Chen YS
J Formos Med Assoc; 2003 Jan; 102(1):30-6. PubMed ID: 12684609
[TBL] [Abstract][Full Text] [Related]
3. Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: a randomized, open-label, controlled trial.
Kim SW; Shin IS; Kim JM; Lee SH; Lee JH; Yoon BH; Yang SJ; Hwang MY; Yoon JS
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1504-9. PubMed ID: 17692448
[TBL] [Abstract][Full Text] [Related]
4. [Evaluation of efficacy and tolerance of amisulpride in treatment of schizophrenic psychoses].
Chabannes JP; Pelissolo A; Farah S; Gerard D
Encephale; 1998; 24(4):386-92. PubMed ID: 9809244
[TBL] [Abstract][Full Text] [Related]
5. Amisulpride for the treatment of very-late-onset schizophrenia-like psychosis.
Psarros C; Theleritis CG; Paparrigopoulos TJ; Politis AM; Papadimitriou GN
Int J Geriatr Psychiatry; 2009 May; 24(5):518-22. PubMed ID: 19072747
[TBL] [Abstract][Full Text] [Related]
6. Fluphenazine (oral) versus atypical antipsychotics for schizophrenia.
Sampford JR; Sampson S; Li BG; Zhao S; Xia J; Furtado VA
Cochrane Database Syst Rev; 2016 Jul; 7(7):CD010832. PubMed ID: 27370402
[TBL] [Abstract][Full Text] [Related]
7. Safety profile of amisulpride in short- and long-term use.
Rein W; Coulouvrat C; Dondey-Nouvel L
Acta Psychiatr Scand Suppl; 2000; 400():23-7. PubMed ID: 10823308
[TBL] [Abstract][Full Text] [Related]
8. Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group.
Peuskens J; Bech P; Möller HJ; Bale R; Fleurot O; Rein W
Psychiatry Res; 1999 Nov; 88(2):107-17. PubMed ID: 10622347
[TBL] [Abstract][Full Text] [Related]
9. Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study.
Sechter D; Peuskens J; Fleurot O; Rein W; Lecrubier Y;
Neuropsychopharmacology; 2002 Dec; 27(6):1071-81. PubMed ID: 12464464
[TBL] [Abstract][Full Text] [Related]
10. Amisulpride compared with standard neuroleptics in acute exacerbations of schizophrenia: three efficacy studies.
Freeman HL
Int Clin Psychopharmacol; 1997 May; 12 Suppl 2():S11-7. PubMed ID: 9218163
[TBL] [Abstract][Full Text] [Related]
11. A double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression.
Vanelle JM; Douki S
Eur Psychiatry; 2006 Dec; 21(8):523-30. PubMed ID: 17113759
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial.
Addington DE; Pantelis C; Dineen M; Benattia I; Romano SJ
J Clin Psychiatry; 2004 Dec; 65(12):1624-33. PubMed ID: 15641867
[TBL] [Abstract][Full Text] [Related]
13. Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study.
Modabbernia A; Rezaei F; Salehi B; Jafarinia M; Ashrafi M; Tabrizi M; Hosseini SM; Tajdini M; Ghaleiha A; Akhondzadeh S
CNS Drugs; 2013 Jan; 27(1):57-65. PubMed ID: 23233269
[TBL] [Abstract][Full Text] [Related]
14. Phase-IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia. The RIS-CAN-3 Study Group.
Chouinard G; Kopala L; Labelle A; Beauclair L; Johnson SV; Singh KI
Can J Psychiatry; 1998 Dec; 43(10):1018-25. PubMed ID: 9868567
[TBL] [Abstract][Full Text] [Related]
15. A 6-week, randomized, multicentre, open-label study comparing efficacy and tolerability of amisulpride at a starting dose of 400 mg/day versus 800 mg/day in patients with acute exacerbations of schizophrenia.
Lee SJ; Lee JH; Jung SW; Koo BH; Choi TY; Lee KH
Clin Drug Investig; 2012 Nov; 32(11):735-45. PubMed ID: 23018281
[TBL] [Abstract][Full Text] [Related]
16. Practical issues with amisulpride in the management of patients with schizophrenia.
Pani L; Villagrán JM; Kontaxakis VP; Alptekin K
Clin Drug Investig; 2008; 28(8):465-77. PubMed ID: 18598092
[TBL] [Abstract][Full Text] [Related]
17. Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology -- a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group.
Wetzel H; Gründer G; Hillert A; Philipp M; Gattaz WF; Sauer H; Adler G; Schröder J; Rein W; Benkert O
Psychopharmacology (Berl); 1998 Jun; 137(3):223-32. PubMed ID: 9682999
[TBL] [Abstract][Full Text] [Related]
18. Amisulpride: a review of its efficacy in schizophrenia.
Möller HJ
Acta Psychiatr Scand Suppl; 2000; 400():17-22. PubMed ID: 10823307
[TBL] [Abstract][Full Text] [Related]
19. Spotlight on amisulpride in schizophrenia.
Curran MP; Perry CM
CNS Drugs; 2002; 16(3):207-11. PubMed ID: 11888341
[TBL] [Abstract][Full Text] [Related]
20. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial.
Assion HJ; Reinbold H; Lemanski S; Basilowski M; Juckel G
Pharmacopsychiatry; 2008 Jan; 41(1):24-8. PubMed ID: 18203048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
